Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study Meeting Abstract
| Authors: | Wang, M.; Shah, N.; Alencar, A.; Gerson, J.; Patel, M.; Fakhri, B.; Jurczak, W.; Tan, X.; Lewis, K.; Fenske, T.; Coombs, C.; Flinn, I.; Lewis, D.; Le Gouill, S.; Palomba, M. L.; Woyach, J.; Pagel, J.; Lamanna, N.; Cohen, J.; Barve, M.; Ghia, P.; Eyre, T.; Zinzani, P. L.; Ujjani, C.; Koh, Y.; Izutsu, K.; Lech-Maranda, E.; Tam, C.; Sundaram, S.; Yin, M.; Nair, B.; Tsai, D.; Balbas, M.; Mato, A.; Cheah, C. |
| Abstract Title: | Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study |
| Meeting Title: | 62nd Annual Scientific Meeting of the British Society for Haematology |
| Journal Title: | British Journal of Haematology |
| Volume: | 197 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Apr 3-5 |
| Meeting Location: | Manchester, United Kingdom |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2022-05-01 |
| Start Page: | 101 |
| End Page: | 104 |
| Language: | English |
| ACCESSION: | WOS:000776484300106 |
| PROVIDER: | wos |
| PUBMED: | 35362090 |
| DOI: | 10.1111/bjh.18134 |
| Notes: | Meeting Abstract: BSH22-PO56 -- Hybrid meeting, also held virtually -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
